Cancer statistics, CA Cancer J Clin, vol.66, issue.1, pp.7-30, 2016. ,
, Ovarian cancer statistics, 2018.
Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer, Crit Rev Oncol Hematol, vol.89, issue.2, pp.207-216, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02181361
Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives, Cancer Treat Rev, vol.59, pp.109-116, 2017. ,
Adoptive immunotherapy against ovarian cancer, J Ovarian Res, vol.9, issue.1, p.30, 2016. ,
, Annu Rev Immunol, vol.18, pp.975-1026, 2000.
?? T cells: first line of defense and beyond, Annu Rev Immunol, vol.32, pp.121-155, 2014. ,
Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue, Immunol Rev, vol.215, pp.123-135, 2007. ,
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human ?? T-cell subset, Blood, vol.120, issue.11, pp.2269-2279, 2012. ,
Molecules and mechanisms implicated in the peculiar antigenic activation process of human V?9V?2 T cells, Front Immunol, vol.5, p.657, 2014. ,
Human ovarian cancer stem-like cells can be efficiently killed by ?? T lymphocytes, Cancer Immunol Immunother. CII, vol.61, issue.7, pp.979-989, 2012. ,
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of V?9V?2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy, Int J Cancer, vol.131, issue.4, pp.449-462, 2012. ,
Stereotaxic administrations of allogeneic human V?9V?2 T cells efficiently control the development of human glioblastoma brain tumors ,
What lessons can be learned from ?? T cell-based cancer immunotherapy trials?, Cell Mol Immunol, vol.5, issue.6, pp.35-41, 2013. ,
First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma, PLoS One, vol.9, issue.3, p.89527, 2014. ,
Paclitaxel inhibits natural killer cell binding to target cells by down-regulating adhesion molecule expression, Anticancer Res, vol.25, pp.735-741, 2005. ,
Involvement of CD166 in the activation of human gamma delta T cells by tumor cells sensitized with nonpeptide antigens, J Immunol Baltim. Md, vol.177, issue.2, pp.877-884, 1950. ,
Tumorgrafts as in vivo surrogates for women with ovarian cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, issue.5, pp.1288-1297, 2014. ,
Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics, Clin Cancer Res Off J Am Assoc Cancer Res, vol.23, issue.5, pp.1263-1273, 2017. ,
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes, Cell Cycle Georget Tex, vol.9, issue.2, pp.260-268, 2010. ,
Zoledronic acid : a review of its use in the management of bone metastases of malignancy, Drugs, vol.68, issue.4, pp.507-534, 2008. ,
Anticancer properties of zoledronic acid, Cancer Invest, vol.28, issue.9, pp.944-957, 2010. ,